Related Experiment Video
Updated: Aug 20, 2026

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion
Christine Buck1, Norbert Bertram, Thomas Ackermann
1Department of General Internal Medicine, University of Bonn, Sigmund-Freud-Strasse 25, Bonn, Germany.
Abstract:
In the present study 24 hospitalized patients requiring empirical antibiotic treatment were randomly assigned to receive the beta-lactam antibiotic/beta-lactamase inhibitor combination piperacillin-tazobactam either as an intermittent or as a continuous infusion. According to pharmacokinetic modelling, the daily dose was reduced by 33% in patients receiving continuous infusion compared with intermittent infusion. Dose reduction because of impaired renal function was required in the intermittent dosing group for 5 of 12 patients compared with 1 of 12 patients in the continuous infusion group. However, the mean daily dose in the continuous group was 15% less than the intermittent infusion group. Mean serum concentrations of piperacillin were to 39.0 microg/ml after the end of bolus distribution, exceeding by far the minimal inhibitory concentration of the most clinically relevant pathogens. The corresponding mean value for tazobactam was 6.3 microg/ml. Pharmacokinetic/pharmacodynamic modelling suggests that both treatment schemes should produce virtually identical anti-infective responses to sensitive, intermediate and resistant strains. In the present study the continuous infusion of piperacillin/tazobactam provided adequate antibacterial activity over the 24-h dosing period and offers the potential for a substantial reduction in the total daily dose.
Insights
Continuous infusion of piperacillin-tazobactam in hospitalized patients allows for a 33% dose reduction. This method ensures adequate antibacterial activity and may reduce the need for dose adjustments in patients with impaired renal function.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Piperacillin-tazobactam is a critical antibiotic combination for empirical treatment.
- Optimizing dosing strategies is essential for efficacy and safety.
Purpose of the Study:
- To compare the pharmacokinetic/pharmacodynamic (PK/PD) profiles of intermittent versus continuous infusion of piperacillin-tazobactam.
- To evaluate the potential for dose reduction and impact on renal function in hospitalized patients.
Main Methods:
- Randomized assignment of 24 hospitalized patients to intermittent or continuous piperacillin-tazobactam infusion.
- Pharmacokinetic modeling to determine optimal dosing.
- Monitoring of serum concentrations and assessment of renal function.
Main Results:
- Continuous infusion allowed for a 33% reduction in daily piperacillin-tazobactam dose compared to intermittent infusion.
- Fewer dose reductions due to renal impairment were needed in the continuous infusion group (1/12 vs 5/12).
- Mean serum concentrations of piperacillin and tazobactam exceeded minimal inhibitory concentrations (MICs) for relevant pathogens.
Conclusions:
- Continuous infusion of piperacillin-tazobactam provides adequate antibacterial activity over 24 hours.
- Continuous infusion offers potential for significant total daily dose reduction and may be advantageous in patients with renal dysfunction.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dosage Interval and Administration Route: Determination Methods
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
IV Infusion to Oral Dosing: Conversion Methods
Drug Accumulation During Multiple Dosing: Repetitive IV Injections

